The systemic and local administration of Bifidobacterium can enhance cancer treatment by reshaping the tumor microenvironment, promoting DCs’ cross-priming, and improving T cell responses through the STING-dependent mechanism.[34] The STING agonist produced by Akkermansia muciniphila enhances the efficacy of immune checkpoint inhibitors by stimulating the production of IFN-I, inducing macrophage reprogramming, and enhancing cross-communication between NK cells and DCs.[33]. Here, STING1 is linked to neoplasm.